What does OOSTVELD - PHARMA do?

OOSTVELD - PHARMA is a pharmacy in Lievegem. Private Limited, started on 15 November 2001, 1 establishment.

What is the address of OOSTVELD - PHARMA?

The registered office of OOSTVELD - PHARMA is located at Oostveld Kouter 171, 9920 Lievegem.

Is OOSTVELD - PHARMA still active?

Yes. According to the CBE (30 October 2026) OOSTVELD - PHARMA is active, legal situation “Normale toestand”, started on 15 November 2001.

Is OOSTVELD - PHARMA registered on Peppol?

Yes, OOSTVELD - PHARMA is registered on the Peppol network with ID 0208:0476087480.

What is the enterprise number of OOSTVELD - PHARMA?

The enterprise number of OOSTVELD - PHARMA is BE0476087480.

When was OOSTVELD - PHARMA founded?

OOSTVELD - PHARMA was founded on 15 November 2001.

Who are the directors of OOSTVELD - PHARMA?

According to the 2025 annual accounts, the directors of OOSTVELD - PHARMA are: Cindy Van Dycke, CILODA BV.

Is OOSTVELD - PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 November 2001; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did OOSTVELD - PHARMA make in 2025?

OOSTVELD - PHARMA posted a profit after taxes of € 135,281 in financial year 2025.

What is the revenue of OOSTVELD - PHARMA?

As a small company, OOSTVELD - PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 393,510.

How much does an employee at OOSTVELD - PHARMA earn?

The average wage cost per full-time employee at OOSTVELD - PHARMA was € 74,900 in 2025: staff costs of € 142,346 for 1.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does OOSTVELD - PHARMA have?

According to the 2025 annual accounts, OOSTVELD - PHARMA has 1.9 full-time equivalents (FTE).

OOSTVELD - PHARMA (Private Limited) - Lievegem

Dossier OOSTVELD - PHARMA, printed on 30 October 2026 from databakkes.be/en/0476087480/oostveld-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

OOSTVELD - PHARMA from Lievegem, company number BE0476087480, closed financial year 2025 with a result of € 135,281 after tax. For that financial year OOSTVELD - PHARMA recorded a gross margin of € 393,510 and equity of € 555,023. Compared with financial year 2024, the result moved from € 140,398 to € 135,281. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.

What it is worth Healthy

€ 555,023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 135,281

▼ 4% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 113,396

▲ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 135,281 paid out

100 % of the profit went to the shareholders, mostly to CILODA (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

1.9

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 142,346

▲ 20% vs 2024

€ 74,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 10,009

▼ 26% vs 2024

Of which on lease € 5,292.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 435,306

▼ 10% vs 2024

€ 48,487 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 88,361

▲ 23% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 27,748

▼ 16% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 299,674 Gross margin 2022: € 299,674 First fiscal year in the series	€ 332,725 Gross margin 2023: € 332,725 ▲ 11% vs 2022 (€ 299,674) Favourable step	€ 380,907 Gross margin 2024: € 380,907 ▲ 14% vs 2023 (€ 332,725) Favourable step	€ 393,510 Gross margin 2025: € 393,510 ▲ 3% vs 2024 (€ 380,907) Favourable step	▲ 3%
Profit after taxes	€ 108,763 Profit after taxes 2022: € 108,763 First fiscal year in the series	€ 102,588 Profit after taxes 2023: € 102,588 ▼ 6% vs 2022 (€ 108,763) Unfavourable step	€ 140,398 Profit after taxes 2024: € 140,398 ▲ 37% vs 2023 (€ 102,588) Favourable step	€ 135,281 Profit after taxes 2025: € 135,281 ▼ 4% vs 2024 (€ 140,398) Unfavourable step	▼ 4%
Equity	€ 555,023 Equity 2022: € 555,023 First fiscal year in the series	€ 555,023 Equity 2023: € 555,023 Unchanged (€ 555,023) Unchanged	€ 555,023 Equity 2024: € 555,023 Unchanged (€ 555,023) Unchanged	€ 555,023 Equity 2025: € 555,023 Unchanged (€ 555,023) Unchanged
Total debts	€ 862,969 Total debts 2022: € 862,969 First fiscal year in the series	€ 757,453 Total debts 2023: € 757,453 ▼ 12% vs 2022 (€ 862,969) Favourable step	€ 743,839 Total debts 2024: € 743,839 ▼ 2% vs 2023 (€ 757,453) Favourable step	€ 702,932 Total debts 2025: € 702,932 ▼ 5% vs 2024 (€ 743,839) Favourable step	▼ 5%
Cash	€ 68,902 Cash 2022: € 68,902 First fiscal year in the series	€ 81,116 Cash 2023: € 81,116 ▲ 18% vs 2022 (€ 68,902) Favourable step	€ 112,082 Cash 2024: € 112,082 ▲ 38% vs 2023 (€ 81,116) Favourable step	€ 113,396 Cash 2025: € 113,396 ▲ 1% vs 2024 (€ 112,082) Favourable step	▲ 1%
Land & buildings	€ 334,287 Land & buildings 2022: € 334,287 First fiscal year in the series	€ 306,516 Land & buildings 2023: € 306,516 ▼ 8% vs 2022 (€ 334,287) Unchanged	€ 278,744 Land & buildings 2024: € 278,744 ▼ 9% vs 2023 (€ 306,516) Unchanged	€ 250,972 Land & buildings 2025: € 250,972 ▼ 10% vs 2024 (€ 278,744) Unchanged	▼ 10%
Retained profit	€ 536,423 Retained profit 2022: € 536,423 First fiscal year in the series	€ 536,423 Retained profit 2023: € 536,423 Unchanged (€ 536,423) Unchanged	€ 536,423 Retained profit 2024: € 536,423 Unchanged (€ 536,423) Unchanged	€ 536,423 Retained profit 2025: € 536,423 Unchanged (€ 536,423) Unchanged
Dividend	€ 108,763 Dividend 2022: € 108,763 First fiscal year in the series	€ 102,588 Dividend 2023: € 102,588 ▼ 6% vs 2022 (€ 108,763) Unchanged	€ 140,398 Dividend 2024: € 140,398 ▲ 37% vs 2023 (€ 102,588) Unchanged	€ 135,281 Dividend 2025: € 135,281 ▼ 4% vs 2024 (€ 140,398) Unchanged	▼ 4%
Bank debt	€ 601,007 Bank debt 2022: € 601,007 First fiscal year in the series	€ 530,384 Bank debt 2023: € 530,384 ▼ 12% vs 2022 (€ 601,007) Favourable step	€ 483,155 Bank debt 2024: € 483,155 ▼ 9% vs 2023 (€ 530,384) Favourable step	€ 435,306 Bank debt 2025: € 435,306 ▼ 10% vs 2024 (€ 483,155) Favourable step	▼ 10%
Balance sheet total	€ 1,417,992 Balance sheet total 2022: € 1,417,992 First fiscal year in the series	€ 1,312,476 Balance sheet total 2023: € 1,312,476 ▼ 7% vs 2022 (€ 1,417,992) Unchanged	€ 1,298,863 Balance sheet total 2024: € 1,298,863 ▼ 1% vs 2023 (€ 1,312,476) Unchanged	€ 1,257,955 Balance sheet total 2025: € 1,257,955 ▼ 3% vs 2024 (€ 1,298,863) Unchanged	▼ 3%
Employees (FTE)	1.6 Employees (FTE) 2022: 1.6 First fiscal year in the series	1.7 Employees (FTE) 2023: 1.7 ▲ 0.1 vs 2022 (1.6) Unchanged	1.9 Employees (FTE) 2024: 1.9 ▲ 0.2 vs 2023 (1.7) Unchanged	1.9 Employees (FTE) 2025: 1.9 Unchanged (1.9) Unchanged

Key figures of OOSTVELD - PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to OOSTVELD - PHARMA?

What happened at OOSTVELD - PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 24, 2026 New annual accounts for financial year 2025: profit of € 135,281 (▼ 4% vs 2024). Source: NBB ↗
2018 CILODA BV became a director. NBB
2010 Cindy Van Dycke became a director. NBB
Jan 7, 2002 New establishment in Lievegem. KBO
Nov 15, 2001 Start of the company according to the CBE. KBO

In short

From € 108,763 profit in 2022 to € 135,281 profit in 2025.

Paid € 124,973 in corporate taxes since 2022.

Best year ever: 2024, with € 140,398 profit.

On average € 207,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

CILODA 100%

The stake of CILODA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

OOSTVELD - PHARMA

Behind OOSTVELD - PHARMA are Cindy Van Dycke and CILODA BV. The shares are held by CILODA (100%).

Directors

According to the 2025 annual accounts

Cindy Van Dycke

Director

Also active at: CILODA

since 2010

CILODA BV

Director · represented by Locy David

Also active at: ARLO

since 2018

Shareholders

CILODA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Oostveld Kouter 171

9920 Lievegem

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

CILODA same network

€ 79,237 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0476.087.480

VAT number

BE 0476.087.480

Registered office

Oostveld Kouter 171, 9920 Lievegem

Names & denominations

OOSTVELD - PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 November 2001

Peppol

Active · Active since 25 Sept 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

OOSTVELD - PHARMA

Financials

What happened to OOSTVELD - PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions